

MARKET REPORT



Dilated Cardiomyopathy Treatment Market: By Treatment Type (Drugs - Beta blockers, Diuretics, Digitalis, Angiotensin II receptor blocker (ARBs), Angiotensin-converting enzyme inhibitors (ACE inhibitors) & Implantable devices - Heart pumps, Cardioverter-defibrillators (ICDs) & Biventricular pacemakers) & By Region-Forecast (2016-2021)

BioPortfolio

Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Dilated Cardiomyopathy Treatment Market: By Treatment Type (Drugs - Beta blockers, Diuretics, Digitalis, Angiotensin II receptor blocker (ARBs), Angiotensin-converting enzyme inhibitors (ACE inhibitors) & Implantable devices - Heart pumps, Cardioverter-defibrillators (ICDs) & Biventricular pacemakers) & By Region-Forecast (2016-2021)

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Dilated Cardiomyopathy Treatment Market: By Treatment Type (Drugs - Beta blockers, Diuretics, Digitalis, Angiotensin II receptor blocker (ARBs), Angiotensin-converting enzyme inhibitors (ACE inhibitors) & Implantable devices - Heart pumps, Cardioverter-defibrillators (ICDs) & Biventricular pacemakers) & By Region-Forecast (2016-2021)

Dilated Cardiomyopathy (DCM) is a condition in which heart's left ventricle, is enlarged and weakened and the ability to pump blood is decreased. The decreased heart function can influence the lungs, liver, and other body systems progressively. It occurs more commonly in male over female and can develop at any age but most common in population between the age group of 20 and 60 years. DCM also leads to frequent blood clots, uneven heartbeats and valve problems. According to American Society for Clinical Investigation, any mutations in genes encoding cytoskeletal proteins or other proteins involved in contraction of myocardial cells accounts for disease in about 25% - 50% of the total affected individuals of Dilated Cardiomyopathy. Other causes include birth defects, drug or alcohol abuse or certain exposure to toxic substances, viral infections of the heart, diabetes, thyroid disorders and heart valve malformations etc.

Two major options used in the treatment of DCM are oral drugs and implantable devices. Oral drugs available are beta blockers, diuretics, digitalis, angiotensin II receptor blocker (ARBs), warfarin and angiotensin-converting enzyme inhibitors (ACE inhibitors). In implantable devices, heart pumps and cardioverter-defibrillators are mainly used.

The growth in DCM treatment market is due to prominent rise in number of heart failure patients worldwide over the years, R&D activities and increased awareness for timely diagnosis.

This report provides information on DCM treatment market size for the year 2014-2016, and forecast of the same for year 2021. It also focuses on market drivers, challenges, restraints, market dynamics, growth indicators, competitive landscape, potential growth opportunities and other key aspects with respect to DCM.

Geographic regions analyzed for this market is divided into four regions i.e. North America, Europe, Asia Pacific and Rest of the World. Due to increase in numbers of heart problems over the years North America and Asia-Pacific are expected to be major markets for DCM. Europe and Row are other prominent markets for the disease.

This report identifies global DCM on the basis of treatment type and regional market as follows:

Dilated Cardiomyopathy treatment market is segmented based on available treatment options. Mainly two treatment options, drugs and implantable devices are in the market

This report is further segmented based on potential markets for DCM. A detailed analysis by region – United States, Europe, Asia-Pacific (APAC) and Rest of the World (RoW), has been provided in this report.

This report looks into all the major companies operating in the DCM treatment. Some of the major companies' profiles are as follows:

AstraZeneca plc.

GlaxoSmithKline Int.

Janssen Pharmaceuticals Inc.

Merck & Co. Inc.

Novartis International AG

Additional Details

Publisher : Industry ARC

Reference : HCR 0276

Number of Pages : 0

Report Format : PDF

Publisher Information :



IndustryARC is the Leading Provider of Market Research Reports, Custom Consulting Services, Data Analytics and Industry Analysis. Our goal is to provide the right information required by the stakeholder at the right point of time, in a format which assists an intelligent and informed decision making process!

We provide profound information with a proactive collaboration with the clients to identify new opportunities and guide them to find the best strategy for finding growth avenues. Our in-depth Research Reports with analysis done by experienced consultants and inputs from industry experts, Key Opinion Leaders (KOLs) span multiple sectors such as:

Table Of Contents for Dilated Cardiomyopathy Treatment Market: By Treatment Type (Drugs - Beta blockers, Diuretics, Digitalis, Angiotensin II receptor blocker (ARBs), Angiotensin-converting enzyme inhibitors (ACE inhibitors) & Implantable devices - Heart pumps, Cardioverter-defibrillators (ICDs) & Biventricular pacemakers) & By Region-Forecast (2016-2021) [Report Updated: 11-03-2016]

- 1. Dilated Cardiomyopathy Treatment – Market Overview2. Executive Summary3. Dilated Cardiomyopathy Treatment - Market Landscape 3.1. Market Share Analysis3.2. Comparative Analysis3.2.1. Product Benchmarking3.2.2. End User Profiling3.2.3. Top 5 Financials Analysis4. Dilated Cardiomyopathy Treatment - Market Forces4.1. Drivers4.1.1. Rise in number of heart failure patients4.2. Restraints4.3. Opportunities4.4. Challenges4.5. Porter’s Five Force Analysis4.5.1. Bargaining Power of Suppliers4.5.2. Bargaining Power of Customers4.5.3. Threat of New Entrants4.5.4. Threat of Substitutes4.5.5. Degree of Competition5. Dilated Cardiomyopathy Treatment Market – Strategic Analysis5.1. Value Chain Analysis5.2. Pricing Analysis5.3. Opportunities Analysis5.4. Product/Market Life Cycle Analysis5.5. Suppliers and Distributors6. Dilated Cardiomyopathy Treatment Market6.1. By type of treatment - Drugs6.1.1. Beta blockers6.1.2. Diuretics6.1.3. Digitalis6.1.4. Angiotensin II receptor blocker (ARBs)6.1.5. Angiotensin-converting enzyme inhibitors (ACE inhibitors)6.2. By type of treatment – Implantable devices6.2.1. Heart pumps6.2.2. Cardioverter-defibrillators (ICDs)6.2.3. Biventricular pacemakers7. Dilated Cardiomyopathy Treatment Market, By Geography7.1. Introduction7.2. America7.2.1. US 7.2.2. Canada7.2.3. Mexico7.3. Europe7.3.1. U.K7.3.2. France7.3.3. Germany7.3.4. Italy7.3.5. Spain7.3.6. Rest of Europe7.4. Asia Pacific7.4.1. China7.4.2. South Korea7.4.3. Japan7.4.4. India7.4.5. Rest of Asia Pacific7.5. RoW8. Market Entropy8.1. Expansion8.2. Technological Developments8.3. Merger & Acquisitions, and Joint Ventures8.4. Supply - Contract9. Company Profiles (By-Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)9.1. GlaxoSmithKline9.2. Pfizer Inc.9.3. Novartis A.G9.4. Merck and Co.9.5. Janssen Pharmaceuticals9.6. AstraZeneca plc.9.7. Array BioPharma, Inc9.8. Vericel Corporation9.9. Celladon Corporation9.10. Teva Pharmaceutical Industries Ltd.*More than 40 Companies are profiled in this Research Report, Complete List available on Request**Financials would be provided on a best efforts basis for private companies"10. Appendix10.1. Abbreviations10.2. Sources10.3. Research Methodology10.4. Expert Insights

List Of Tables in Dilated Cardiomyopathy Treatment Market: By Treatment Type (Drugs - Beta blockers, Diuretics, Digitalis, Angiotensin II receptor blocker (ARBs), Angiotensin-converting enzyme inhibitors (ACE inhibitors) & Implantable devices - Heart pumps, Cardioverter-defibrillators (ICDs) & Biventricular pacemakers) & By Region-Forecast (2016-2021) [Report Updated: 11-03-2016]

No

How to Buy...

Dilated Cardiomyopathy Treatment Market: By Treatment Type (Drugs - Beta blockers, Diuretics, Digitalis, Angiotensin II receptor blocker (ARBs), Angiotensin-converting enzyme inhibitors (ACE inhibitors) & Implantable devices - Heart pumps, Cardioverter-defibrillators (ICDs) & Biventricular pacemakers) & By Region-Forecast (2016-2021) [Report Updated: 11-0-2016]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/80327>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$5250** | Single User Price
- \$6250** | Site License Price
- \$8450** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.